Publications en 2018

Arcaini L, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J, Rule S, Cabecadas J, Campo E, Pileri SA, Biyukov T, Patturajan M, Casadebaig Bravo ML, Trneny M, 2018. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator’’s choice in relapsed or refractory mantle cell lymphoma. Br. J. Haematol. 180, 224–235. https://doi.org/10.1111/bjh.15025

Barbieux S, Boyle EM, Baillet C, Demarquette H, Vermersch P, Morschhauser F, Herbaux C, 2018. Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin’’s lymphoma. Curr Res Transl Med. https://doi.org/10.1016/j.retram.2018.04.004 

Barnoud D, Pinçon C, Bruno B, Béné J, Gautier S, Lahoche A, Petitpain N, Vasseur M, Barthélémy C, Décaudin B, Simon N, Odou P, 2018. Acute kidney injury after high dose etoposide phosphate: A retrospective study in children receiving an allogeneic hematopoetic stem cell transplantation. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.27038 

Beauvais D, Goossens JF, Boyle E, Allal B, Lafont T, Chatelut E, Herbaux C, Morschhauser F, Genay S, Odou P, Danel C, 2018. Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1093–1094, 158–166. https://doi.org/10.1016/j.jchromb.2018.06.026 

Belaiche S, Decaudin B, Dharancy S, Gautier S, Noel C, Odou P, Hazzan M, 2018. Factors associated with the variability of calcineurin inhibitor blood levels in kidney recipients grafted for more than 1 year. Fundam. Clin. Pharmacol. 32, 88–97. https://doi.org/10.1111/fcp.12328 

Benlabed M, Martin Mena A, Gaudy R, Perez M, Genay S, Hecq JD, Odou P, Lebuffe G, Décaudin B, 2018a. Analysis of particulate exposure during continuous drug infusion in critically ill adult patients: a preliminary proof-of-concept in vitro study. Intensive Care Med Exp 6, 38. https://doi.org/10.1186/s40635-018-0205-2 

Benlabed M, Perez M, Gaudy R, Genay S, Lannoy D, Barthélémy C, Odou P, Lebuffe G, Décaudin B, 2018b. Clinical implications of intravenous drug incompatibilities in critically ill patients. Anaesth Crit Care Pain Med. https://doi.org/10.1016/j.accpm.2018.04.003 

Besson A, Baillet C, Herbaux C, Foucher C, Lambilliotte A, Morschhauser F, Huglo D, 2018. Variability of hepatic SUVs and SULs in response assessment of avid FDG lymphoma during chemotherapy. Med. Nucl.-Imag. Fonct. Metab. 42, 114–124. https://doi.org/10.1016/j.mednuc.2018.02.004 

Blasco H, Patin F, Descat A, Garçon G, Corcia P, Gelé P, Lenglet T, Bede P, Meininger V, Devos D, Gossens JF, Pradat PF, 2018. A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression. PLoS ONE 13, e0198116. https://doi.org/10.1371/journal.pone.0198116 

Bollier M, Klupsch F, Six P, Dubuquoy L, Azaroual N, Millet R, Leleu-Chavain N, 2018. One- or Two-Step Synthesis of C-8 and N-9 Substituted Purines. J. Org. Chem. 83, 422–430. https://doi.org/10.1021/acs.joc.7b02269 

Bouthors AS, Hennart B, Jeanpierre E, Baptiste AS, Saidi I, Simon E, Lannoy D, Duhamel A, Allorge D, Susen S, 2018. Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial. Trials 19. https://doi.org/10.1186/s13063-017-2420-7 

Caiazzo R, Baud G, Clément G, Lenne X, Torres F, Dezfoulian G, Lebuffe G, Kipnis E, Dervaux B, Pattou F, 2018. Impact of Centralized Management of Bariatric Surgery Complications on 90-day Mortality. Ann. Surg. https://doi.org/10.1097/SLA.0000000000002949 

Catry E, Bindels LB, Tailleux A, Lestavel S, Neyrinck AM, Goossens JF, Lobysheva I, Plovier H, Essaghir A, Demoulin JB, Bouzin C, Pachikian BD, Cani PD, Staels B, Dessy C, Delzenne NM, 2018. Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. Gut 67, 271–283. https://doi.org/10.1136/gutjnl-2016-313316 

Cuvelier E, Mequinion M, Leghay C, Sibran W, Stievenard A, Sarchione A, Bonte MA, Vanbesien-Mailliot C, Viltart O, Saitoski K, Caron E, Labarthe A, Comptdaer T, Semaille P, Carrie H, Mutez E, Gressier B, Destee A, Chartier-Harlin MC, Belarbi K, 2018. Overexpression of Wild-Type Human Alpha-Synuclein Causes Metabolism Abnormalities in Thy1-aSYN Transgenic Mice. Front. Molec. Neurosci. 11. https://doi.org/10.3389/fnmol.2018.00321 

Decanter C, Robin G, Mailliez A, Sigala J, Morschhauser F, Ramdane N, Devos P, Dewailly D, Leroy-Martin B, Keller L, 2018. Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controls. Reprod. Biomed. Online. https://doi.org/10.1016/j.rbmo.2018.01.016 

Decroix L, Tonoli C, Lespagnol E, Balestra C, Descat A, Drittij-Reijnders MJ, Blackwell JR, Stahl W, Jones AM, Weseler AR, Bast A, Meeusen R, Heyman E, 2018. One week CF intake increases prefrontal cortex oxygenation at rest and during moderate-intensity exercise in normoxia and hypoxia. J. Appl. Physiol. https://doi.org/10.1152/japplphysiol.00055.2018 

Domenger D, Cudennec B, Kouach M, Touche V, Landry C, Lesage J, Gosselet F, Lestavel S, Goossens JF, Dhulster P, Ravallec R, 2018. Food-Derived hemorphins cross intestinal and Blood-Brain Barriers In Vitro. Front. Endocrinol. 9. https://doi.org/10.3389/fendo.2018.00159 

Ducloy-Bouthors AS, Jeanpierre E, Saidi I, Baptiste AS, Simon E, Lannoy D, Duhamel A, Allorge D, Susen S, Hennart B, 2018. TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial. Trials 19. https://doi.org/10.1186/s13063-017-2421-6 

Federico M, Barrigon MDC, Marcheselli L, Tarantino V, Manni M, Sarkozy C, Alonso-Alvarez S, Wondergem M, Cartron G, Lopez-Guillermo A, Issa D, Morschhauser F, Alcoceba M, Kimby E, Rusconi C, Chamuleau M, Holte H, Lockmer S, Montoto S, da Silva MG, Aurer I, Zucca E, Paszkiewicz-Kozik E, Minoia C, Skrypets T, Blaker YN, Salles G, Coiffier B, 2018. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 5, E359–E367. https://doi.org/10.1016/S2352-3026(18)30090-5 

Ferret L, Ficheur G, Delaviez E, Luyckx M, Quenton S, Beuscart R, Chazard E, Beuscart JB, 2018. Inappropriate anticholinergic drugs prescriptions in older patients: analysing a hospital database. Int. J. Clin. Phar,. 40, 94–100. https://doi.org/10.1007/s11096-017-0554-z 

Flamme-Obry F, Belaiche S, Hazzan M, Ramdan N, Noël C, Odou P, Décaudin B, 2018. [Clinical pharmacist and medication reconciliation in kidney transplantation]. Nephrol. Ther. https://doi.org/10.1016/j.nephro.2017.04.004 

Foulon C, Di Giulio P, Lecoeur M, 2018. Simultaneous determination of inorganic anions and cations by supercritical fluid chromatography using evaporative light scattering detection. J. Chromatogr. A 1534, 139–149. https://doi.org/10.1016/j.chroma.2017.12.047 

Gelli M, Allard MA, Farges O, Paugam-Burtz C, Mabrut JY, Regimbeau JM, Vibert E, Boleslawski E, 2018. Use of aspirin and bleeding-related complications after hepatic resection. Br J Surg. https://doi.org/10.1002/bjs.10697 

Gibault F, Coevoet M, Sturbaut M, Farce A, Renault N, Allemand F, Guichou JF, Drucbert AS, Foulon C, Magnez R, Thuru X, Corvaisier M, Huet G, Chavatte P, Melnyk P, Bailly F, Cotelle P, 2018. Toward the Discovery of a Novel Class of YAPTEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAPTEAD ProteinProtein Interface. Cancers (Basel) 10. https://doi.org/10.3390/cancers10050140 

Gilliot S, Sibon I, Mas JL, Moulin T, Béjot Y, Cordonnier C, Giroud M, Odou P, Bordet R, Vivien D, Leys D, 2018. Influence of on-going treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke. J. Neurol. https://doi.org/10.1007/s00415-018-8827-6 

Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, Haverkos B, 2018. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. https://doi.org/10.1182/blood-2018-02-811174 

Jannin A, Turpin A, Baillet C, Aubert S, Do Cao C, 2018. High 18F-FDG Avidity of Low-Grade Esthesioneuroblastoma. Clin. Nucl. Med. 43, e101–e102. https://doi.org/10.1097/RLU.0000000000001962

Masse M, Maton M, Genay S, Blanchemain N, Barthélémy C, Décaudin B, Odou P, 2018. In vitro assessment of the influence of intravenous extension set materials on insulin aspart drug delivery. PLoS ONE 13, e0201623. https://doi.org/10.1371/journal.pone.0201623 

Morschhauser F, Dekyndt B, Baillet C, Barthélémy C, Malek E, Fulcrand J, Bigot P, Huglo D, Décaudin B, Simon N, Odou P, 2018a. Y-ibritumomab tiuxetan based on 3-dimensional dosimetry. Sci Rep 8, 14860. https://doi.org/10.1038/s41598-018-33160-0 

Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA, 2018b. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N. Engl. J. Med. 379, 934–947. https://doi.org/10.1056/NEJMoa1805104 

Morschhauser F, Salles G, Le Gouill S, Tilly H, Thieblemont C, Bouabdallah K, Fabiani B, Ménard C, Tarte K, Cartron G, Houot R, 2018c. An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. Blood. https://doi.org/10.1182/blood-2018-05-853499 

Perez M, Décaudin B, Abou Chahla W, Nelken B, Storme L, Masse M, Barthélémy C, Lebuffe G, Odou P, 2018. Effectiveness of in-Line Filters to Completely Remove Particulate Contamination During a Pediatric Multidrug Infusion Protocol. Sci Rep 8, 7714. https://doi.org/10.1038/s41598-018-25602-6 

Robert L, Ficheur G, Décaudin B, Gellens J, Luyckx M, Perichon R, Gautier S, Puisieux F, Chazard E, Beuscart JB, 2018. Hospital-acquired hyperkalemia events in older patients are mostly due to avoidable, multifactorial, adverse drug reactions. Clin. Pharmacol. Ther. https://doi.org/10.1002/cpt.1239 

Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H, 2018. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers. Am. J. Hematol. https://doi.org/10.1002/ajh.25154 

Simon N, Barnoud D, Bruno B, Vasseur M, Béné J, Odou P, 2018. Should we replace etoposide phosphate by etoposide for allogeneic hematopoetic stem-cell transplantation in children? Pediatr Blood Cancer. https://doi.org/10.1002/pbc.27039 

Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Le Gouill S, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabecadas J, Becker S, Jardin F, Mounier N, Salles G, 2018a. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. Lancet Haematol. 5, E403–E410. 

Tilly H, Salles G, Molina TJ, Casasnovas RO, Morschhauser F, Coiffier B, 2018b. Through the Glass Ceiling. J. Clin. Oncol. JCO2017763961. https://doi.org/10.1200/JCO.2017.76.3961 

Van den Neste E, André M, Gastinne T, Stamatoullas A, Haioun C, Belhabri A, Reman O, Casasnovas O, Guesquieres H, Verhoef G, Claessen MJ, Poirel HA, Copin MC, Dubois R, Vandenberghe P, Stoian IA, Cottereau AS, Bailly S, Knoops L, Morschhauser F, 2018. Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica. https://doi.org/10.3324/haematol.2017.180554 

Vasseur M, Simon N, Picher C, Richeval C, Soichot M, Humbert L, Barthélémy C, Fleury-Souverain S, Bonnabry P, Décaudin B, Allorge D, Odou P, 2018. A decontamination process adding a tensioactive agent and isopropanol to a closed-system drug transfer device for better control of isolator contamination. A prospective, parallel study. PLoS ONE 13, e0201335. https://doi.org/10.1371/journal.pone.0201335 

Vo DN, Alexia C, Allende-Vega N, Morschhauser F, Houot R, Menard C, Tarte K, Cartron G, Villalba M, 2018. NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment. OncoImmunology 7. https://doi.org/10.1080/2162402X.2017.1409322 

Walther J, Nivoix Y, Vigouroux D, Simon N, Debry C, Gourieux B, 2018. Improvement of drugs prescription and administration through enteral feeding tubes during hospitalization and before discharge to home. Nutr. Clin. Metab. 32, 113–121. https://doi.org/10.1016/j.nupar.2017.12.002

Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU, 2018. Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: A retrospective analysis based on the prospective, international, multicenter PTLD-1 trials. Transplantation. https://doi.org/10.1097/TP.0000000000002269

 

Livre - Chapitre de livre

Revue sans comité de lecture